SAFFRON: Osimertinib Plus Savolitinib May Set a New Standard of Care for Patients With Advanced NSCLC After Progression on EGFR-TKI Treatment
Patients with advanced non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and MET alterations whose disease progressed on osimertinib experienced statistically significant benefits in progression-free survival and overall survival from the addition of the MET tyrosine kinase inhibitor savolitinib to osimertinib vs platinum/pemetrexed in subsequent lines of treatment in the phase III SAFFRON trial.1,2 The study’s primary results were presented at the European Society for Medical Oncology (ESMO) Congress 2026 by Shun Lu, MD, PhD, of the Department of Medical Oncology at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
‘New Global Standard of Care’
In the full analysis set, median progression-free survival was 7.6 months with osimertinib plus savolitinib vs 5.4 months with platinum-pemetrexed chemotherapy (hazard ratio [HR] = 0.55; P < .001), representing a 45% reduction in the risk of disease progression or death. Median overall survival with osimertinib plus savolitinib vs platinum-pemetrexed chemotherapy with data that were 53% mature at the time of analysis, was 17.8 months vs 12.9 months (HR = 0.68; P = .010), translating to a 32% reduction in the risk of death. Twelve-month overall survival rates were 70% vs 53%.
“Osimertinib plus savolitinib establishes a new global standard of care for patients with EGFR-mutant advanced non–small cell lung cancer with MET overexpression and/or amplification after progression on osimertinib,” Dr. Lu said.
As Dr. Lu explained, despite advances in first-line therapies, most patients with EGFR-mutant advanced NSCLC eventually experience disease progression. MET dysregulation is a key mechanism of resistance to EGFR tyrosine kinase inhibitors, including osimertinib, with MET protein overexpression and/or MET gene amplification reported in 34% of patients whose disease progressed on osimertinib. Patients with MET-mediated resistance have poor outcomes, and targeted treatment options are limited.
“SAFFRON establishes the clinical value of an all-oral biomarker-directed treatment approach targeting both EGFR and MET following progression on osimertinib, reinforcing osimertinib as a backbone treatment across lines of therapy,” he said.
About SAFFRON
The global SAFFRON trial screened 1,746 patients with locally advanced or metastatic EGFR-mutated NSCLC whose disease had progressed on first- or second-line osimertinib as their most recent therapy. Of these, 338 met eligibility criteria and were randomly assigned in a 1:1 fashion. The investigational arm (n = 171) was assigned to receive osimertinib at 80 mg once-daily plus savolitinib at 300 mg twice-daily; the control arm (n = 167) received pemetrexed at 500 mg/m2 plus a platinum agent (carboplatin at an area under the concentration-time curve of 5 or cisplatin at 75 mg/m2) once every 3 weeks for four 21-day cycles, followed by pemetrexed at 500 mg/m2 as maintenance therapy once every 3 weeks.
MET overexpression, defined as immunohistochemistry (IHC) 3+ staining intensity in ≥ 90% of tumor cells, and/or MET amplification, defined as ≥ 10 MET gene copies as assessed by fluorescence in situ hybridization (FISH), had to be centrally confirmed using a post-progression tissue biopsy. The primary endpoint was progression-free survival.
More Study Results
Progression-free survival benefits with osimertinib plus savolitinib were observed across all prespecified subgroups, including patients with baseline brain metastases (HR = 0.50). At 12 months, 36% of patients in the experimental arm vs 10% in the control arm remained alive and progression-free in the full analysis set, Dr. Lu reported.
“Progression-free survival by blinded independent central review in the MET-overexpressed and MET-amplified analysis sets was generally consistent with the full analysis set,” he said. In the MET-overexpressed analysis set, median progression-free survival was 8.5 months with the combination vs 5.6 months with chemotherapy (HR = 0.51; P < .001). In the MET-amplified analysis set, for which no formal statistical testing was performed, the corresponding values were 7.6 and 4.2 months, respectively (HR = 0.48; 95% confidence interval =0.35–0.66).
“Tumor response endpoints all favored the osimertinib plus savolitinib arm,” he said. Objective response rates were 51% in the combination arm vs 27% in the chemotherapy arm (odds ratio [OR] = 2.90), and disease control rates were 85% vs 65%, respectively (OR = 3.18). The median best percentage change in target lesion size was –44% vs –25%, and the median duration of response was 9.7 months vs 5.7 months, respectively.
Grade ≥ 3 treatment-related adverse events occurred less often with the combination than with chemotherapy (40% vs 52%), and treatment-emergent peripheral edema, considered by the investigator to have a reasonable possibility of being caused by the study treatment, occurred in 49% of patients with the combination. One fatal adverse event (pneumonia), considered possibly related to study treatment, occurred in the combination arm. At the time of the data cutoff, 26% of treated patients in the combination arm remained on at least one study treatment compared with 2% in the chemotherapy arm.
A new drug application seeking approval of osimertinib plus savolitinib for patients with locally advanced or metastatic NSCLC with MET overexpression and/or amplification whose disease had progressed on or after EGFR-targeted therapy was submitted to the U.S. Food and Drug Administration in September 2026. In China, the combination is approved for patients with EGFR-mutated, MET-amplified nonsquamous NSCLC after progression on an EGFR tyrosine kinase inhibitor.
DISCLOSURE: Dr. Lu has consulted or advised for AstraZeneca, Pfizer, and Takeda. Research was supported by AstraZeneca.
REFERENCES
1. Lu S, Girard N, Okuma Y, et al: Osimertinib plus savolitinib vs platinum-pemetrexed in patients with EGFRm advanced NSCLC with MET overexpression and/or amplification after progression on osimertinib: SAFFRON phase III primary results. 2026 ESMO Congress. Abstract LBA6. Presented October 24, 2026.
2. Lu S, Girard N, Yang JC-H, et al: Osimertinib-savolitinib in advanced NSCLC after progression during EGFR-TKI therapy. N Engl J Med. Published October 25, 2026.
EXPERT POINT OF VIEW
In the phase III SAFFRON trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 by Lu et al, patients with advanced non–small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and MET alterations whose disease progressed on osimertinib experienced statistically significant benefits in progression-free survival and overall survival from the addition of the MET tyrosine kinase inhibitor savolitinib to osimertinib vs platinum/pemetrexed in subsequent lines of treatment.1
SAFFRON’s invited discussant Natasha B. Leighl, MD, FRCPC, FASCO, a Professor of Medicine at the University of Toronto and the Daniel E. Bergsagel Chair in Medical Oncology at Princess Margaret Cancer Centre, lauded the study’s design, findings, and clinical implications, noting that combining tyrosine kinase inhibitors that target EGFR and MET “has always been a winning strategy” but “it just took the SAFFRON team to bring it home.”
She called SAFFRON a well-designed, well-balanced study with valid and meaningful results. “We see that at one year, 25% more patients are alive and progression-free and 70% are alive…We will see how this evolves…hopefully these curves will continue to separate…If anything, perhaps this is a real success,” she said, adding that small confirmatory studies in China have replicated the strong signal seen here. “But there are no easy fixes,” she cautioned, emphasizing that careful monitoring for toxicities, dose reductions, and prophylactic strategies will be important in managing this combination.
“Have we met a new standard of care? Yes, we have. This is the first study in lung cancer following progression on osimertinib to demonstrate improved progression-free and overall survival with an oral combination over intravenous chemotherapy in a molecularly defined population,” Dr. Leighl said. “When we go back to clinic, we must ensure that every patient gets a biopsy, gets testing, and then gets matched to the best possible therapy or trial. We must then ensure drug access, addressing issues of regulatory authorities and cost.”
DISCLOSURE: Dr. Leighl has received travel support from AstraZeneca, MSD, Roche, Johnson & Johnson, Regeneron, Sanofi, and Guardant Health.
REFERENCE
1. Lu S, Girard N, Okuma Y, et al: Osimertinib plus savolitinib vs platinum-pemetrexed in patients with EGFRm advanced NSCLC with MET overexpression and/or amplification after progression on osimertinib: SAFFRON phase III primary results. 2026 ESMO Congress. Abstract LBA6. Presented October 24, 2026.